Last reviewed · How we verify
without COPADM3
This drug targets the PD-1 receptor to inhibit cancer cell growth.
At a glance
| Generic name | without COPADM3 |
|---|---|
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
By blocking the PD-1 receptor, the drug prevents cancer cells from evading the immune system, allowing the body's immune cells to attack and destroy the cancer cells. This leads to an anti-tumor response and potentially long-term remission.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- without COPADM3 CI brief — competitive landscape report
- without COPADM3 updates RSS · CI watch RSS
- Gustave Roussy, Cancer Campus, Grand Paris portfolio CI